Iovance Biotherapeutics, Inc.

NASDAQ:IOVA

Biotechnology

Healthcare
$7.48 -0.89%

-$0.04 today

Market cap
$3.46B
Beta
0.70
P/E (TTM)
-4.6
EPS (TTM)
-$0.85
52W Low $1.66High $5.63

Volume 6.99M

Average 14.09M

IOVA Income Before Tax

Profit after all operating and non-operating items but before income tax.

Iovance Biotherapeutics, Inc.NASDAQ: IOVA

Income Before Tax · Q3 FY2026 · quarter ended Sep 2026

Income before tax remains negative

Q3 FY2026 income before tax was -$21.66M, compared with -$93.66M a year earlier. Trailing-twelve-month income before tax was -$221.78M.

Context

  • Income before tax amounted to 149.2% of revenue in FY2025, down 79.4 pp from a year earlier.
  • Income before tax grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly income before tax holds near -$21.66M or moves back toward the trailing-twelve-month quarterly average of -$55.44M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$21.66M+55.5% QoQ
Last fiscal yearDec 2025
-$393.05M-4.8% YoY
LTMSep 2026
-$221.78M+44.3% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+76.9%——
1 year-4.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(393.05M) USD
Year-over-year change
-4.8%

Income Before Tax vs competitors

How IOVA compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +44.3% is the 3rd highest of 10, against a peer median of +26.1%.
  • Income before tax amounts to 58.5% of revenue for IOVA, versus a peer median of 61.9%.
IOVA Competitors
Income Before Tax for IOVA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GMABGenmab A/SLTM Jun 2026$906.11M USD—-44.2%21.9%
LEGNLegend Biotech CorporationLTM Sep 2026$32.2M USD+114.5%—2.4%
IMCRImmunocore Holdings plcLTM Mar 2026-$7.82M USD+65.7%—2.0%
STTKShattuck Labs, Inc.LTM Mar 2026-$49.87M USD+29.4%—4987.4%
ALXOALX Oncology Holdings Inc.LTM Mar 2026-$88.87M USD+31.7%——
FATEFate Therapeutics, Inc.LTM Mar 2026-$129.91M USD+26.1%—2056.8%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026-$221.78M USD+44.3%—58.5%
IMNMImmunome, Inc.LTM Sep 2026-$282.65M USD-26.9%——
REPLReplimune Group, Inc.LTM Dec 2025-$315.82M USD-38.7%——
IBRXImmunityBio, Inc.LTM Sep 2026-$1.11B USD-218.3%—607.9%
BNTXBioNTech SELTM Jun 2026-€1.64B EUR-321.6%—61.9%
Peer median (excluding IOVA) —+26.1%-44.2%61.9%

Competitors are the stored peer set for IOVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue001.19M164.07M263.5M
Cost of Revenue0010.76M124M173.18M
Gross Profit00(9.57M)40.08M90.32M
Gross Margin——-804.5%24.4%34.3%
Research & Development259.04M294.78M344.08M282.34M300.27M
Selling, General & Admin83.66M104.1M106.92M153.02M152.32M
Operating Expenses342.7M398.88M450.99M435.35M488.53M
Depreciation & Amortization13.98M21.14M33.13M43.61M47.32M
EBITDA(328.27M)(371.77M)(414.39M)(331.4M)(350.89M)
EBITDA Margin——-34851.9%-202.0%-133.2%
Operating Income(342.7M)(398.88M)(460.56M)(395.28M)(398.21M)
Operating Margin——-38735.0%-240.9%-151.1%
Interest Income451K2.99M13.04M20.27M10.31M
Interest Expense02.99M000
Other Income / Expenses451K2.99M13.04M20.27M5.16M
Income Before Tax(342.25M)(395.89M)(447.52M)(375.01M)(393.05M)
Pre-Tax Margin——-37638.0%-228.6%-149.2%
Income Tax Expense00(3.48M)(2.83M)(2.07M)
Net Income(342.25M)(395.89M)(444.04M)(372.18M)(390.98M)
Net Margin——-37345.4%-226.8%-148.4%
EPS (Basic)(2.23)(2.49)(1.89)(1.28)(1.09)
EPS (Diluted)(2.23)(2.49)(1.89)(1.28)(1.09)
Weighted Avg Shares153.41M159.26M235.13M289.88M357.35M
Weighted Avg Shares (Diluted)153.41M159.26M235.13M289.88M357.35M

Iovance Biotherapeutics, Inc.

NASDAQ:IOVA

Intrinsic Alpha fair value

Locked

Current Price

$7.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.